Results 61 to 70 of about 5,721 (196)
Arthritis &Rheumatology, Volume 78, Issue 4, Page 985-992, April 2026.Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty +4 more
wiley +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Review is devoted to the role of modern beta-blocker nebivolol in the treatment of stable ischemic heart disease (IHD). The mode of nebivolol anti-ischemic activity is considered, as well as its use particularities in IHD patients with different ...
V. P. Lupanov
doaj +1 more source
Nebivolol-induced gynecomastia
Journal of Pharmacology and Pharmacotherapeutics, 2015 Adverse drug reactions play a substantial role in the etiology of gynecomastia. Gynecomastia as an adverse drug reaction, related to some cardiovascular drugs, has been reported in literature. Nebivolol is a third generation beta-blocker, and gynecomastia as an adverse effect on the consumption of this drug has not been reported in any article yet.
Köklü, Erkan +4 more
openaire +3 more sources
The Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.Abstract Labetalol is widely prescribed as a first‐line antihypertensive in pregnancy; however, rare but potentially severe idiosyncratic hepatotoxicity has been reported, with a disproportionately strong reporting signal for liver injury relative to other β‐blockers.
Emma D. Hendriksen +2 more
wiley +1 more source
, 1993 (D-L) Nebivolol is a new beta 1-selective adrenoceptor blocker which in normal individuals preserves rest and exercise hemodynamics. We assessed the effects of the enantiomers (L- and D-nebivolol) on left ventricular (LV) systolic and diastolic function ...
Bouvy, T. +5 more
core +1 more source
NEBIVOLOL IN TREATMENT OF STABLE EXERTIONAL ANGINA PECTORIS
Рациональная фармакотерапия в кардиологии, 2015 Aim. To evaluate antianginal and antiischemic efficiency of nebivolol in patients with stable angina pectoris.Material and methods. 100 patients with ischemic heart disease showing stable exertional angina pectoris and having no contraindications to beta-
Y. V. Gavrilov +2 more
doaj +1 more source
Cancer Neuroscience: Innovative Conception and Emerging Strategy of Therapy
MedComm, Volume 7, Issue 4, April 2026.In this review, we summarize nerve–cancer interactions and conclude two additional interactions, “perineural invasion” and “neuro‐microbic‐oncology.” Emphasizing the important role of nerves in tumor progression. The nervous system also contributes to the development of cancer comorbidities such as cancer depression and cognitive dysfunction.
Ting Wang +5 more
wiley +1 more source
The Journal of Clinical Hypertension, Volume 28, Issue 4, April 2026.ABSTRACT Pseudoxanthoma elasticum (PXE) is a rare autosomal recessive disorder caused by pathogenic variants in ABCC6, leading to progressive calcification of elastic fibers. Although PXE typically presents in adolescence with dermatologic or ocular manifestations, early vascular involvement, including pediatric hypertension, is increasingly recognized.
Hana Flogelova +8 more
wiley +1 more source
Effects of nebivolol on human platelet aggregation.
, 2001 It has been documented that beta-adrenergic antagonists can influence platelet aggregation by a mechanism independent of their ability to antagonize beta-adrenoceptors.
D'AGOSTINO, Bruno +15 more
core +2 more sources
Рациональная фармакотерапия в кардиологии, 2016 Aim. To compare effects of 12-month monotherapy with nebivolol, enalapril and indapamide on blood pressure (BP), left ventricular hypertrophy and quality of life in the locomotive engineers and their assistants with stress-associated hypertension at the ...
О. N. Antropova +4 more
doaj +1 more source